Clinical Trial Update: Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab plus tremelimumab with concurrent radiotherapy for localized muscle-invasive bladder cancer treated with a selective bladder…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Spanish Oncology Genito-Urinary Group | Conditions: Invasive Bladder Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-12-05